Pharma's quiet price ladder, decoded

New York — The injectable arrived on the market eight years ago with a list price of $1,180 a month. It treats a common autoimmune condition, works much as its predecessors did, and has not been meaningfully reformulated since launch. Today its list price is $2,940 — a 149 per cent climb in a stretch when general inflation rose by roughly a fifth. The molecule did not change. The disease did not change. What changed, according to four people who have worked inside the pricing departments of large drugmakers and pharmacy intermediaries, is the size of the discount the manufacturer agreed to hand back, invisibly, to the companies that decide which drugs patients can actually obtain.

This is the open secret of American drug pricing: the number printed on the invoice is increasingly a fiction, and the gap between that fiction and the price anyone actually pays has become the product itself. To understand why a class of widely used drugs has ratcheted upward in near-lockstep, you have to follow not the medicine but the rebate.

The list price fiction

Every prescription drug carries a wholesale acquisition cost, or WAC — the manufacturer's published list price. It is the figure that drives headlines, that anchors a patient's coinsurance, and that almost no large purchaser pays. Sitting between the manufacturer and the patient is a pharmacy benefit manager, or PBM, which negotiates on behalf of insurers and employers. The PBM extracts a rebate off the list price in exchange for favourable placement on the formulary — the menu of drugs a plan will cover.

The mechanics create a perverse gravity. Because the rebate is calculated as a percentage of list, a higher list price can yield a larger absolute rebate even when the net price the manufacturer keeps stays flat or falls. A drugmaker can raise its sticker by 10 per cent, hand most of that increase back as a deeper rebate, and end up roughly where it started — while the PBM pockets a bigger cheque and the patient, whose copay is pegged to list, pays more.

The sticker goes up so the discount can go up. The patient stands underneath both.

The rebate machine

Meridian reviewed contract summaries and net-price data for a basket of six drugs in a single therapeutic class, compiled from manufacturer disclosures, insurer filings and a pricing-analytics dataset shared on condition it not be named. The pattern is consistent: list prices marched upward year after year while net prices — what manufacturers actually collected after rebates — stayed nearly still.

Across the basket, the average rebate share — the portion of list clawed back before the manufacturer sees a cent — rose from roughly 38 per cent in 2018 to 57 per cent in 2025. In other words, for every dollar on the invoice, fifty-seven cents now flows back through the chain. Where exactly it lands is the part no one will put on paper.

Who keeps the spread

The rebate does not simply vanish into the patient's premium. It is split, and the split is where the opacity hardens. A portion is passed to the insurer or employer to lower premiums. A portion is retained by the PBM as an administrative fee, often pegged — again — to the list price, so that a higher sticker enlarges the fee even when the rebate is nominally passed through. A third sliver moves through group purchasing organisations and rebate aggregators, several of which are owned by the same parent companies as the PBMs themselves.

You can pass through 100 per cent of the rebate and still make a fortune, because you've moved the money into a fee on a number you helped inflate. The contract is technically honest and economically meaningless.Former pricing executive at a large PBM

The three largest PBMs are each housed within a corporation that also owns an insurer and a mail-order pharmacy. That vertical integration means a single parent can sit on multiple sides of the same transaction — negotiating the rebate, collecting the fee, paying the pharmacy and insuring the patient. None of it is illegal. Almost none of it is visible to the person at the counter.

What the patient actually pays

For an insured patient, the cruelty is procedural. Coinsurance is calculated against list, not net, so a patient paying 20 per cent of a $2,940 drug owes $588 — even though the system behind her settled the drug for $1,090. She is, in effect, paying a percentage of a number designed to be discounted away from everyone but her.

• Patients in high-deductible plans frequently pay the full list price until their deductible is met, capturing none of the rebate negotiated on their behalf.
• Manufacturer copay cards blunt the pain at the pharmacy but are increasingly intercepted by "copay accumulator" programmes that prevent the assistance from counting toward a deductible.
• The uninsured, who have no PBM negotiating for them, are billed closest to the undiscounted list — the highest price in the chain falls on those least able to absorb it.

Why the ladder holds

No single actor in this chain has an incentive to break it. The manufacturer wants formulary access and can raise list without losing net. The PBM wants a bigger fee and rebate base. The insurer wants the premium relief the rebate funds. Each rational decision, stacked together, produces a system that climbs and a patient bill that climbs faster — a price ladder whose every rung is someone's reasonable self-interest.

Reform proposals circle the same fixes: delinking PBM fees from list price, requiring rebates to flow to patients at the point of sale, or forcing net-price disclosure. Each has been introduced, diluted and shelved more than once. The structure persists not because it is defended openly but because it is understood by so few — and because the money it moves is large enough to fund the lobbying that keeps it dim.

What remains unresolved is whether transparency alone would change anything. Disclosing net prices would expose the gap, but the incentive to inflate list survives any disclosure as long as someone's fee is pegged to it. Until the arithmetic is rewired — until a higher sticker no longer pays anyone more — the ladder will keep climbing, quietly, one rebate at a time, and the reason will stay exactly where it has always been kept: out of sight of the person paying for it.